CRIS Current Research Information System

MASSARI, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 16.525
NA - Nord America 8.964
EU - Europa 5.160
SA - Sud America 1.238
AF - Africa 610
OC - Oceania 19
Continente sconosciuto - Info sul continente non disponibili 6
Totale 32.522
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.688
SG - Singapore 4.723
CN - Cina 4.304
VN - Vietnam 3.288
IT - Italia 1.686
HK - Hong Kong 1.400
BR - Brasile 953
KR - Corea 840
BD - Bangladesh 580
GB - Regno Unito 540
IN - India 471
DE - Germania 467
SE - Svezia 425
NL - Olanda 391
FR - Francia 360
FI - Finlandia 255
CH - Svizzera 230
RU - Federazione Russa 217
JP - Giappone 212
SC - Seychelles 199
IE - Irlanda 166
CA - Canada 146
CI - Costa d'Avorio 131
AR - Argentina 126
ZA - Sudafrica 121
ID - Indonesia 102
PH - Filippine 102
AT - Austria 74
TH - Thailandia 68
MX - Messico 67
TR - Turchia 65
IQ - Iraq 63
BG - Bulgaria 61
JO - Giordania 49
TG - Togo 49
PK - Pakistan 47
PL - Polonia 46
UA - Ucraina 45
ES - Italia 44
TW - Taiwan 42
EC - Ecuador 37
BE - Belgio 30
EE - Estonia 30
VE - Venezuela 30
CO - Colombia 27
SA - Arabia Saudita 26
MY - Malesia 24
CL - Cile 23
UZ - Uzbekistan 23
AU - Australia 18
KE - Kenya 17
NG - Nigeria 15
PY - Paraguay 15
UY - Uruguay 15
EG - Egitto 14
JM - Giamaica 14
LT - Lituania 14
AZ - Azerbaigian 13
IL - Israele 12
TN - Tunisia 12
PE - Perù 11
PT - Portogallo 11
MA - Marocco 10
GR - Grecia 9
HR - Croazia 9
LB - Libano 9
AE - Emirati Arabi Uniti 8
AL - Albania 8
CR - Costa Rica 8
DZ - Algeria 8
NP - Nepal 8
KZ - Kazakistan 7
RO - Romania 7
TT - Trinidad e Tobago 7
HN - Honduras 6
OM - Oman 6
PS - Palestinian Territory 6
CZ - Repubblica Ceca 5
ET - Etiopia 5
GT - Guatemala 5
IR - Iran 5
KG - Kirghizistan 5
SN - Senegal 5
BH - Bahrain 4
BY - Bielorussia 4
HU - Ungheria 4
NI - Nicaragua 4
PR - Porto Rico 4
XK - ???statistics.table.value.countryCode.XK??? 4
CD - Congo 3
CY - Cipro 3
DO - Repubblica Dominicana 3
GH - Ghana 3
LV - Lettonia 3
RS - Serbia 3
SK - Slovacchia (Repubblica Slovacca) 3
SV - El Salvador 3
SY - Repubblica araba siriana 3
BB - Barbados 2
GD - Grenada 2
Totale 32.475
Salva come PNG Salva come JPEG
Città #
Singapore 3.193
Hefei 1.770
Hong Kong 1.331
Ashburn 1.022
Ho Chi Minh City 856
San Jose 855
Seoul 800
Hanoi 764
Boardman 531
Santa Clara 456
Fairfield 375
Beijing 364
Southend 355
Chandler 311
Council Bluffs 307
Los Angeles 288
Bologna 278
New York 245
Bern 207
Lauterbourg 191
Helsinki 188
Seattle 188
Milan 183
Bengaluru 166
Tokyo 166
Dublin 164
Wilmington 162
Buffalo 160
Woodbridge 160
Houston 154
Dallas 147
Abidjan 131
Cambridge 131
Da Nang 129
Princeton 127
Dong Ket 122
São Paulo 116
Redondo Beach 108
Rome 96
Haiphong 85
Guangzhou 78
Boydton 73
Nuremberg 71
Shanghai 70
Ann Arbor 69
Turin 67
Frankfurt am Main 65
Johannesburg 64
Jakarta 62
Chicago 60
Lappeenranta 56
Sofia 55
Tongling 54
Amsterdam 49
Lomé 49
Amman 48
Castel Maggiore 46
Florence 46
Nanjing 46
Hải Dương 43
Montreal 43
Phoenix 43
Biên Hòa 41
Vienna 40
Westminster 39
Redmond 36
Can Tho 35
San Francisco 34
Berlin 33
Quận Bình Thạnh 33
Changsha 32
Munich 32
Orem 31
Falkenstein 30
London 30
Ninh Bình 30
Rio de Janeiro 30
Denver 29
Thái Nguyên 29
Warsaw 29
Atlanta 28
Jinan 28
Shenzhen 28
Brooklyn 27
Brussels 27
Ha Long 27
Hyderabad 27
Mexico City 26
Naples 26
Paris 26
San Diego 26
Tianjin 26
Toronto 26
Zhengzhou 25
Padova 24
Redwood City 24
Salt Lake City 24
Xi'an 24
Bari 23
Boston 23
Totale 19.747
Salva come PNG Salva come JPEG
Nome #
Multi-Gene Next-Generation Sequencing Panel for Analysis of BRCA1/BRCA2 and Homologous Recombination Repair Genes Alterations Metastatic Castration-Resistant Prostate Cancer 269
First-line Systemic Therapy Following Adjuvant Immunotherapy in Renal Cell Carcinoma: An International Multicenter Study 256
Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors: Sensitivity and meta-regression analysis of randomized trials 249
Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis 229
A case of complete response to nivolumab after long-term progression-free survival with tyrosine kinase inhibitor. 229
H&E and OCT4/CD34 for the assessment of lympho-vascular invasion in seminoma and embryonal carcinoma 224
INTRAHEPATIC CHOLANGIOCARCINOMA DEVELOPMENT IN A PATIENT WITH A NOVEL BAP1 GERMLINE MUTATION AND LOW EXPOSURE TO ASBESTOS 219
Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System 215
Circulating tumor cells in genitourinary tumors 215
Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience 207
Insights into the impact of chromosome 3p mutations in advanced renal cell carcinoma treated with immune-based combinations or targeted therapy: A single-center experience 206
Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial 195
Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective Experience 193
Liver metastases from prostate cancer at 11C-Choline PET/CT: a multicenter, retrospective analysis 188
Clinical management of a pituitary gland metastasis from clear cell renal cell carcinoma. 186
223Ra-chloride therapy in men with hormone-refractory prostate cancer and skeletal metastases: Real-world experience. 182
Chromosome 3p gene alterations as biomarkers for immunocombinations in metastatic renal cell carcinoma: A hypothesis-generating analysis 178
CARE-compliant stereotactic radiotherapy of urothelial nodal metastases: A case report 178
Dynamics of resistance to immunotherapy and TKI in patients with advanced renal cell carcinoma 178
Sopravvivenza di pazienti con recidiva vaginale di carcinoma endometriale: il ruolo della radioterapia e della chirurgia. 177
Tumor growth rate to assess therapy response to immune-based combinations for metastatic renal cell carcinoma 176
Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapy 176
Dual-energy spectral CT in renal cell carcinoma: dawn of a brand-new era? 175
Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer 175
Oestrogen receptor 1 mRNA is a prognostic factor in ovarian cancer patients treated with neo-adjuvant chemotherapy: determination by array and kinetic PCR in fresh tissue biopsies. 171
State of the art of adjuvant immunotherapy in urothelial cancer: New developments and upcoming changes 170
Novel Immune Checkpoint Inhibitor Targets in Advanced or Metastatic Renal Cell Carcinoma: State of the Art and Future Perspectives 168
Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer 168
Real-World Outcomes and Molecular Profiling for Patients with Metastatic Castration-resistant Prostate Cancer with Lung Metastases: A Long-term Multicenter Experience 166
Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw 165
Bone targeting agents in patients with metastatic prostate cancer: State of the art 165
Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study 163
Analysis of GATA3 and FOXA2 expression suggests that downregulation of genes involved in the maintenance of a mature yolk sac tumor phenotype may underlie sarcomatoid transformation 161
Mutations of NOTCH Genes as an Alternative Mechanism to Activate mTOR pathway in Low-grade Oncocytic Tumor (LOT) of the Kidney 161
Cabozantinib-related cardiotoxicity: a prospective analysis in a "real world" cohort of metastatic renal cell carcinoma patients 161
TAMs PD-L1(+) in the reprogramming of germ cell tumors of the testis 159
Bone targeting agents, but not radiation therapy, improves survival in patients with bone metastases from advanced urothelial carcinoma receiving pembrolizumab: results from the ARON-2 study 158
Broad spectrum mutational analysis of chromophobe renal cell carcinoma using next-generation sequencing 157
Immune checkpoint inhibitors for metastatic bladder cancer 156
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study 155
A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy 155
Adjuvant therapy in renal cell carcinoma: Is it the right strategy to inhibit VEGF? 153
A prospective study on the early evaluation of response to androgen receptor-targeted agents with 11C-Choline, 68Ga-PSMA, and 18F-FACBC PET in metastatic castration-resistant prostate cancer: a single-center experience 151
Detection of liver lesions during 11C-Choline PET/CT in relapsing prostate cancer patients 151
Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach 150
The value of molecular features in predicting efficacy of immuno-combinations in kidney cancer: just a drop in the ocean? 149
Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations 149
Circulating Tumor Cells: A Reliable Biomarker for Prostate Cancer Treatment Assessment? 149
FoxA2 is a reliable marker for the diagnosis of yolk sac tumour postpubertal-type 148
Evaluation of an institutional series of low-grade oncocytic tumor (LOT) of the kidney and review of the mutational landscape of LOT 148
New Hormonal Agents in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: Meta-Analysis of Efficacy and Safety Outcomes. 148
Expected and non-expected immune-related adverse events detectable by CT 147
The human microbiota and prostate cancer: Friend or foe? 146
First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 study 145
The Tumor Entity Denominated “clear cell-papillary renal cell carcinoma” According to the WHO 2016 new Classification, have the Clinical Characters of a Renal Cell Adenoma as does Harbor a Benign Outcome 142
Is There a Role for Immunotherapy in Prostate Cancer? 141
Chemotherapy in metastatic renal cell carcinoma today? A systematic review 140
Tumor growth rate decline despite progressive disease may predict improved nivolumab treatment outcome in mrcc: When recist is not enough 140
Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier? 138
Mirna Expression in Bladder Cancer and Their Potential Role in Clinical Practice 137
Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer 137
Sex as modifier of survival in patients with advanced urothelial cancer treated with pembrolizumab 136
Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics 136
Immortal time bias question in the association between toxicity and outcome of immune checkpoint inhibitors 136
Genomics and Immunomics in the Treatment of Urothelial Carcinoma 135
Immune-checkpoint inhibitors in previously treated patients with advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis 135
Immune modulation in prostate cancer patients treated with androgen receptor (Ar)-targeted therapy 134
Targeting the Programmed Cell Death-1 Pathway in Genitourinary Tumors: Current Progress and Future Perspectives 133
Impact of HER2 assessment by CISH in urothelial carcinoma: A retrospective single-center experience 132
Similarities and differences between clear cell tubulo-papillary and conventional clear cell renal cell carcinoma: A comparative phenotypical and mutational analysis 131
Hypertransaminasemia in metastatic renal cell carcinoma patients receiving immune-based combinations: a meta-analysis 130
Narrative review of prostate cancer grading systems: Will the Gleason scores be replaced by the grade groups? 130
Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de-differentiation (ARON-1 study) 130
Belzutifan: enhancing the blockade of angiogenesis in renal cell carcinoma 130
Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: Where do we stand? 130
Immunohistochemical over-expression of HER2 does not always match with gene amplification in invasive bladder cancer 129
Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1) 128
Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study 127
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study 126
Sex differences in adverse events among cancer patients receiving immune checkpoint inhibitors: the MOUSEION-07 systematic review and meta-analysis 126
Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib 126
BAP1 in solid tumors 126
Avelumab Plus Intermittent Axitinib in Previously Untreated Patients with Metastatic Renal Cell Carcinoma. The Tide-A Phase 2 Study 125
Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: A systematic review 125
Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: A meta-analysis 124
Urinary biomarkers for prostate cancer 123
Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC Criteria in Patients With Metastatic Renal Cell Carcinoma: A Validation Study 123
Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors 122
The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System 122
Storage Time and DNA Quality Determine BRCA1/2 Sequencing Success in Prostate Cancer: A Multicentre Analysis with Therapeutic Implications 121
A Meta-Analysis Evaluating Clinical Outcomes of Patients with Renal Cell Carcinoma Harboring Chromosome 9P Loss. 121
Update on circulating tumor cells in genitourinary tumors with focus on prostate cancer 120
The prospect of precision therapy for renal cell carcinoma. 120
Characterization of testicular embryonic-type neuroectodermal tumor and embryonic-type neuroectodermal tissue admixed with mature neuro-glial tissue using a broad immunohistochemical panel 119
Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study) 119
Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations 118
Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy. 118
Overall survival with adjuvant pembrolizumab in renal cell carcinoma — the shock of the lightning 117
The Prognostic Role of 68GA-PSMA-PET/CT in Metastatic Hormone-Sensitive Prostate Cancer: A Preliminary Analysis 117
Assessing the effectiveness and safety of lenvatinib and everolimus in advanced renal cell carcinoma: insights from the RELIEVE study's analysis of heavily pretreated patients 116
Totale 15.459
Salva come PNG Salva come JPEG
Categoria #
all - tutte 106.339
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 106.339
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021341 0 0 0 0 0 0 0 0 0 0 0 341
2021/20221.091 46 33 41 81 88 56 41 101 133 47 282 142
2022/20232.575 112 151 59 169 214 460 212 129 388 70 228 383
2023/20241.133 131 171 94 95 84 140 37 93 56 91 73 68
2024/20257.012 209 688 728 406 851 255 453 209 224 428 828 1.733
2025/202619.451 2.136 2.466 2.287 1.684 1.516 644 1.566 604 2.715 1.556 1.172 1.105
Totale 33.467